These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9180192)

  • 1. Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults.
    Gellin BG; Greenberg RN; Hart RH; Bertino JS; Stein DH; Deloria MA; Clements-Mann ML
    J Infect Dis; 1997 Jun; 175(6):1494-7. PubMed ID: 9180192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
    Van Der Meeren O; Peterson JT; Dionne M; Beasley R; Ebeling PR; Ferguson M; Nissen MD; Rheault P; Simpson RW; De Ridder M; Crasta PD; Miller JM; Trofa AF
    Hum Vaccin Immunother; 2016 Aug; 12(8):2197-2203. PubMed ID: 27123743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.
    Wiedmann M; Liebert UG; Oesen U; Porst H; Wiese M; Schroeder S; Halm U; Mössner J; Berr F
    Hepatology; 2000 Jan; 31(1):230-4. PubMed ID: 10613751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
    Jafarzadeh A; Zarei S; Shokri F
    Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens.
    Clements ML; Miskovsky E; Davidson M; Cupps T; Kumwenda N; Sandman LA; West D; Hesley T; Ioli V; Miller W
    J Infect Dis; 1994 Sep; 170(3):510-6. PubMed ID: 8077707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.
    Li J; Yao J; Shan H; Chen Y; Jiang ZG; Ren JJ; Xu KJ; Ruan B; Yang SG; Wang B; Xie TS; Li Q
    Hum Vaccin Immunother; 2015; 11(5):1108-13. PubMed ID: 25607773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.
    Wang ZZ; Gao YH; Lu W; Jin CD; Zeng Y; Yan L; Ding F; Li T; Liu XE; Zhuang H
    Hum Vaccin Immunother; 2017 Apr; 13(4):909-915. PubMed ID: 27874311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprotection after hepatitis B vaccination in chronic kidney disease patients with modified schedule and dosage.
    Siddiqui S; Malik A; Shukla I; Rizvi M; Haque SF
    J Infect Dev Ctries; 2010 Jun; 4(6):389-92. PubMed ID: 20601791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses.
    Lai CL; Wong BC; Yeoh EK; Lim WL; Chang WK; Lin HJ
    Hepatology; 1993 Oct; 18(4):763-7. PubMed ID: 8406348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.
    Das K; Gupta RK; Kumar V; Kar P
    World J Gastroenterol; 2003 May; 9(5):1132-4. PubMed ID: 12717874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.
    Cassidy WM; Watson B; Ioli VA; Williams K; Bird S; West DJ
    Pediatrics; 2001 Apr; 107(4):626-31. PubMed ID: 11335734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China.
    Zhang L; Liu J; Lu J; Yan B; Song L; Li L; Cui F; Zhang G; Wang F; Liang X; Xu A
    Hum Vaccin Immunother; 2015; 11(11):2716-22. PubMed ID: 26252481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of HBV vaccine during stated shelf-life.
    Gloriani NG; Srinivasa K; Bock HL; Hoet B
    Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and long-term durability of intradermal recombinant hepatitis B virus vaccine among intramuscular vaccine nonresponders: A prospective study in healthcare personnel.
    Kalchiem-Dekel O; Grupel D; Bouchnik L; Sikuler E; Ben-Yakov G
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1782-7. PubMed ID: 26101816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.